Clinical Trial

Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 24, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-11-30; most recent amendment 2025-02-21.
Trial Details
NCT Number NCT05633446
Lead Sponsor Gylden Pharma Ltd
Conditions Coronavirus, SARS-CoV-2 Infection, COVID-19
Enrollment 110 participants
Start Date 2025-09-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-24